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PAcute Coronary Syndromes
Randomized Comparison of High
lopidogrel Loading Doses in Patients With
on–ST-Segment Elevation Acute Coronary Syndromes
he ALBION (Assessment of the Best Loading Dose of Clopidogrel
o Blunt Platelet Activation, Inflammation and Ongoing Necrosis) Trial
illes Montalescot, MD, PHD,* Georges Sideris, MD,† Catherine Meuleman, MD,‡
laire Bal-dit-Sollier, MB,§ Nicolas Lellouche, MD, Ph. Gabriel Steg, MD,¶ Michel Slama, MD,#
livier Milleron, MD,** Jean-Philippe Collet, MD, PHD,* Patrick Henry, MD,† Farzin Beygui, MD, PHD,*
udovic Drouet, MD, PHD,§ for the ALBION Trial Investigators
aris, France
OBJECTIVES We sought to compare the antiplatelet effects of three clopidogrel loading doses (LDs).
BACKGROUND Administration of a 300-mg clopidogrel LD is beneficial in situations requiring rapid platelet
inhibition. Whether higher LDs can provide further benefits remains unknown.
METHODS Patients (n  103) with non–ST-segment elevation acute coronary syndromes were randomized
to receive a 300-mg, 600-mg, or 900-mg clopidogrel LD, given on top of other standard therapy
(including acetylsalicylic acid). The main outcome measure was inhibition of adenosine
diphosphate-induced inhibition of platelet aggregation (IPA); inhibition of platelet activa-
tion, inflammatory markers, troponin I release, and major adverse cardiac events also were
evaluated; all measures were blindly evaluated.
RESULTS Compared with the 300-mg LD, greater doses were associated with significantly greater
platelet inhibition, with dose-effect relationships observed for onset of action, maximal
plateau, 24-h areas under the curves of IPA, and rates of low IPA (10% at 6 h), using 20
mol/l major adverse cardiac events. A significant dose-response was also observed for the
vasodilator-stimulated phosphoprotein index, a measure of P2Y12 receptor inhibition. Similar
but nonsignificant trends were observed for troponin release and major adverse cardiac events.
Bleeding rates were similar in each group.
CONCLUSIONS In low-to-moderate risk patients with non–ST-elevation acute coronary syndromes, clopi-
dogrel LDs 300 mg provide a faster onset of action, a higher IPA plateau, and greater
reductions in platelet activation during the first 24 h. A 900-mg LD may induce a greater
antiplatelet effect than 600 mg, when compared with the standard 300-mg regimen. These
findings require further clinical confirmation. (J Am Coll Cardiol 2006;48:931–8) © 2006
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.04.090by the American College of Cardiology Foundation
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tptimal and rapid inhibition of platelet function is an
mportant therapeutic goal for the management of patients
ith acute coronary syndromes and in those undergoing
ercutaneous coronary intervention (PCI). In the case of
ntiplatelet therapy with clopidogrel, a P2Y12 adenosine
iphosphate (ADP)-receptor antagonist, this has tradition-
lly been achieved by initiating treatment with a 300-mg
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hat they have been consultants for and/or have received research grants from
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Manuscript received September 26, 2005; revised manuscript received April 20,
006, accepted April 25, 2006.ral loading dose (LD) to reduce the time to onset of action
rom a few days to a few hours (1), with a significant clinical
enefit in addition to acetylsalicylic acid (ASA), in various
ituations (2–10).
However, the slow onset of action still remains a question
n the urgent care setting and/or PCI and has led several
roups to conduct small randomized studies evaluating
reater LDs (i.e., 400 to 600 mg) of clopidogrel. Most of
hese studies have suggested that greater LDs reduce the
ime to achieve optimal inhibition of platelet aggregation
IPA) (11–13), although divergent results have also been
ublished (14,15). Recent data also have suggested an
ncremental benefit of a 600-mg LD (compared with the
tandard 300-mg LD) on the release of cardiac markers
fter PCI (13,16). These studies typically have been single
enter and open label, with a limited number of sampling
ime points; all have used clopidogrel LDs 600 mg.
To address the question of the optimal clopidogrel LD
igorously, we performed a randomized, multicenter,
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The ALBION Trial September 5, 2006:931–8arallel-group evaluation of the effects of three different
lopidogrel LDs, testing a dose as high as 900 mg. In this
ose-ranging study, multiple sampling time points were
sed to precisely determine the onset of action and the
iming of the maximal effect on inhibition of platelet
unction with the different LDs. Although evaluation of
latelet aggregation (PA) was the primary objective of the
tudy, platelet activation and markers of inflammation and
ecrosis also were evaluated during the first 24 h. To avoid
ny interaction of PCI on the kinetics of all these markers,
t was decided to study patients with non–ST-segment
levation acute coronary syndrome (NSTE-ACS) before
hey presented to the catheterization laboratory. Finally,
schemic and bleeding events were closely monitored during
month of follow-up.
ETHODS
tudy design. The ALBION (Assessment of the best Load-
ng dose of clopidogrel to Blunt platelet activation, Inflam-
ation and Ongoing Necrosis) trial was a randomized,
arallel-group study of patients hospitalized with NSTE-
CS with a blinded evaluation of the primary end point and
ll biological secondary end points. The study was con-
ucted at seven cardiology centers in Paris, France, accord-
ng to the principles of the Helsinki Declaration and the
nternational Conference on Harmonisation of Technical
equirements for Registration of Pharmaceuticals for Hu-
an Use guidelines for Good Clinical Practice. Approval
as obtained from the Pitié-Salpêtrière University Hospital
thics Committee, and patients provided written informed
onsent.
Major inclusion criteria were: 1) age 18 and 85 years;
) ischemic symptoms (onset 48 h) and at least one of
he following: electrocardiogram ST-segment or T-wave
hanges or positive troponin; 3) treatment at hospital
Abbreviations and Acronyms
ADP  adenosine diphosphate
ASA  acetylsalicylic acid
AUC  area under the inhibition of platelet
aggregation curve
GP  glycoprotein
IPA  inhibition of platelet aggregation
LD  loading dose
LMWH  low molecular weight heparin
MACE  major adverse cardiac events
MFI  median fluorescence intensity
NSTE-ACS  non–ST-segment elevation acute coronary
syndrome
PA  platelet aggregation
PAI  plasminogen activator inhibitor
PCI  percutaneous coronary intervention
PGE1  prostaglandin E1
sCD40L  soluble CD40 ligand
VASP  vasodilator-stimulated phosphoprotein
vWF Ag  von Willebrand factor antigendmission with 250 to 500 mg of oral or intravenous ASA snd low molecular weight heparin (LMWH); and 4) an
ssignment for clopidogrel treatment.
Major exclusion criteria were: 1) catheterization performed
efore randomization or scheduled to be performed 24 h
fter randomization; 2) contraindication to LMWH, clopi-
ogrel, or ASA; 3) severe hypertension; 4) platelet count
100,000/mm3; 5) neutrophil count 1800/mm3; 6) in-
reased risk of bleeding; and 7) recent (within 10 days) or
lanned use of nonpermitted concomitant medications (any
ntiplatelet agent other than ASA, oral anticoagulants,
irudin, nonsteroidal anti-inflammatory drugs). In case of
mergent PCI or glycoprotein (GP) IIb/IIIa inhibitor use
uring the 24-h study period, the patient was excluded from
he analysis.
reatment and follow-up. Using central randomization,
atients were allocated to receive a 300-, 600-, or 900-mg
ral clopidogrel LD on the morning of day 1. Twenty-four
ours after the LD, all patients were started on a regimen of
lopidogrel 75 mg/day and ASA 100 mg/day. Low
olecular weight heparin was administered twice daily. All
tudy medication was administered on an open-label basis.
atients were followed up at 30 (7) days to record clinical
utcome and adverse event reporting.
rocessing of samples. To ensure prompt sample transfer
nd assaying, patients could only be randomized if the
aseline blood sample was to be taken between 7 AM and 11
M between Monday and Friday. The blood samples were
ransferred by the delivery service to the central laboratory,
rriving within 1 h of venipuncture. Platelet aggregometry
nd flow cytometry tests were blindly performed immedi-
tely upon receipt.
ssay methods. Aggregometry, flow cytometry, measure-
ents of inflammatory biomarkers, and markers of myone-
rosis at all time points during the 24 h were processed in
he core laboratory that was blinded to the treatment
eceived.
DENOSINE DIPHOSPHATE-INDUCED PLATELET AGGREGA-
ION. Platelet-rich plasma was obtained by centrifugation
f citrated whole blood at 100 g for 15 min at room
emperature. Platelet-poor plasma was obtained by further
entrifugation at 1000 g for 20 min. In vitro PA in
latelet-rich plasma was measured at 37°C in an aggregometer
Model 490-4D, Chrono-Log Corporation, Kordia, the
etherlands) following the optical aggregometry method of
orn (17). Platelet aggregation was induced by the addition
f ADP (Chrono-Par, Kordia, the Netherlands) at final
oncentrations of 5 mol/l and 20 mol/l, and PA param-
ters were measured on samples obtained at baseline, 0.5 h, 1 h,
h, 3 h, 4 h, 5 h, 6 h, and 24 h. Inhibition of platelet
ggregation (%) at time Tx was (intensity of aggregation at T
aseline)  (intensity of aggregation at Tx)/(intensity of
ggregation at T baseline).
LOW CYTOMETRY. Flow cytometry measurements were
erformed at the same nine time points. All flow cytometric
tudies were conducted on a FACScalibur flow cytometer
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September 5, 2006:931–8 The ALBION TrialBecton Dickinson, Franklin Lakes, New Jersey) using
ellQuest software (Becton Dickinson) for data acquisition
nd analysis. Analyses were performed on citrated whole
lood diluted 1:4 in phosphate-buffered saline incubated
ith either PAC1 fluorescein isothiocyanate-conjugated
onoclonal antibody (Becton Dickinson), anti-P-selectin
hycoerythrin-conjugated monoclonal antibody (Becton
ickinson), or anti-fibrinogen fluorescein isothiocyanate-
onjugated polyclonal antibody (Dako, Trappes, France).
latelet activation markers were measured in unstimulated
latelets and after stimulation of platelets with ADP (5 mol/l
nal concentration). In addition, the phosphorylation of
asodilator-stimulated phosphoprotein (VASP) was measured
t 6 and 24 h by quantitative flow cytometry using a commer-
ially available kit from Diagnostica Stago/Biocytex (Marseille,
rance). The VASP index was calculated from the median
uorescence intensity (MFI) of samples incubated with pros-
aglandin E1 (PGE1) and ADP according to the formula:
ASP index  [(MFI(PGE1)  MFI(PGE1  ADP))/
FI(PGE1)]  100.
NFLAMMATORY MARKERS. Determinations were performed
n samples obtained at baseline, 6 h, and 24 h using commer-
ially available enzyme-linked immunosorbent assays. High-
ensitivity C-reactive protein in serum was measured using
highly sensitive kit (Dade-Behring, Paris la Défense,
rance). von Willebrand factor antigen (vWF Ag) and
lasminogen activator inhibitor (PAI)-1 antigen were mea-
ured in citrated plasma (Asserachrom, Stago, Asnières,
rance). Soluble CD40 ligand (sCD40L) was measured in
erum (R&D Systems, Lille, France).
ROPONIN I. Troponin I measurements were performed on
amples taken at baseline, 6 h, and 24 h, with serum concen-
rations measured by immunoassay using an AXSYM analyzer
Abbott, Rungis, France). Patients with an increasing tro-
onin were defined as either patients with a negative
roponin on admission becoming positive over the course of
4 h or patients with a positive troponin on admission
ncreasing by 30%, during the first 24 h.
ND POINTS. The primary objective of the study was to
valuate changes in PA (IPA, %). The kinetic profile of
lopidogrel-mediated IPA induced by 5 mol/l ADP was
ompared across the three groups with respect to change
rom baseline to each time point and maximum effect. The
ame criteria were applied to the kinetic profile of inhibition
f 20 mol/l ADP-induced PA.
Among the secondary objectives of the study were the
inetics of inhibition of platelet activation (activated GP
Ib/IIIa receptor complexes, P-selectin expression, fibrino-
en binding, P-VASP); the frequency of low response
defined as IPA 10% at 6 h); the impact on markers of
nflammation (C-reactive protein, vWF Ag, PAI-1 antigen,
CD40L); the effect on troponin I (a marker of myonecro-
is); the incidence of death, myocardial infarction, or isch-
mic recurrences leading to revascularization and/or rehos- titalization; and the safety profile using the GUSTO
Global Utilization of Streptokinase and TPA for Ocluded
rteries) (18) definitions of bleeding.
TATISTICAL ANALYSES. The time course of the change
rom baseline to the maximum intensity of PA induced by
DP was compared through an analysis of variance of the
hanges from baseline at each time point. A Student t test,
sing the common residual variance from the global analysis
f variance, was used to make pairwise comparisons between
he 300-mg group and each of the higher LDs at each time
oint. No adjustment for multiple comparisons was made.
he following comparisons were performed: 300 mg versus
00 mg and 300 mg versus 900 mg. The area under the IPA
urve (AUC) was calculated and compared across dosages
sing an analysis of variance. This AUC was a combination
f the level of inhibition with the duration of the inhibition.
he platelet activation parameters were analyzed using the
ame model of analysis of variance but after log transforma-
ion of the number of epitopes. Qualitative variables were
ompared using the Pearson chi-square test or the Fisher
xact test when the calculated sample size of at least 1 cell of
table was 5.
ESULTS
total of 103 patients with NSTE-ACS were enrolled into
he study. Baseline demographic characteristics are listed in
able 1. Overall, there were no statistically significant differ-
nces between the treatment groups.
nhibition of platelet aggregation. In the 300-mg LD
roup, maximal inhibition of 5 mol/l ADP-induced PA
as achieved by 6 h after the initiation of clopidogrel.
reater LDs were associated with a significantly faster onset
f inhibition (within the first 6 h: p  0.05 at 3 time points
ith both 600 mg and 900 mg vs. 300 mg) (Table 2). In
ddition, the greater clopidogrel LDs produced significantly
reater maximal IPA compared with the 300-mg LD. For
ach of the higher LDs, this significant increment in platelet
nhibition was still observed at 24 h (Fig. 1A, Table 2).
Using 20 mol/l ADP, the kinetics of IPA were faster
ith 900 mg, which produced already significantly greater
PA at 1 h after the administration of clopidogrel than with
00 mg (Fig. 1B). Within 2 h, the level of IPA obtained
ith 900 mg was greater than that obtained at the plateau of
PA with 300 mg. The onset of action of the 600-mg dose was
ntermediate between the 300- and 900-mg dose groups. A
imilar dose-effect relationship was found for the maximal
lateau of IPA. Significantly higher inhibition was found at all
ime points from 1 to 24 h with 900 mg versus 300 mg.
ntermediate levels were measured with 600 mg, which were
nly statistically different from 300 mg at the 4-h time point
p 0.04) (Table 2).
Comparison of the 24-h AUCs for IPA suggested again
dose-response effect, with statistically significant higher
UCs in the 600-mg and 900-mg groups compared withhe 300-mg group (Fig. 2).
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The ALBION Trial September 5, 2006:931–8Interestingly, although maximal IPA increased with in-
reasing doses, it was obtained between 5 and 6 h in all three
roups with both 5 and 20 mol/l ADP-induced PA.
atients with less than 10% of IPA at 6 h, a time point
hen maximal IPA was reached in all 3 groups, were
pecifically analyzed. When using 5 mol/l, the percentages
f patients with a low response (IPA 10% at 6 h) were
8.6%, 17.2%, and 7.1% with 300, 600, and 900 mg,
espectively (p  0.20). When using 20 mol/l, these rates
ere 46.4%, 20.7%, and 10.7% with 300, 600, and 900 mg,
espectively (p  0.007).
latelet activation. All clopidogrel LDs reduced platelet
embrane expression of PAC-1, P-selectin, and fibrinogen
fter stimulation. Peak reductions in these markers occurred
t 5 to 6 h after administration of each clopidogrel LD. At
h, stimulated PAC-1 expression was reduced significantly
n both the 600- and 900-mg groups as compared to the
able 2. p Values for Comparisons of Effects of Different
oading Doses on Inhibition of Platelet Aggregation
Sampling
Time (h)
5 mol/l ADP 20 mol/l ADP
600 mg vs.
300 mg
900 mg vs.
300 mg
600 mg vs.
300 mg
900 mg vs.
300 mg
0.5 0.196 0.905 0.241 0.881
1.0 0.399 0.196 0.269 0.038
2.0 0.049 0.039 0.325 0.030
3.0 0.002 0.009 0.054 0.017
4.0 0.002 0.012 0.040 0.014
5.0 0.093 0.063 0.120 0.015
6.0 0.163 0.061 0.129 0.012
24.0 0.023 0.017 0.179 0.011
able 1. Baseline Demographics
Clopidogrel, 3
(n  35)
ge, mean (SD), yrs 59.7 (11.8
en, no. (%) 27 (77.1
eight, mean (SD), kg 78.1 (17.5
ymptoms onset, no. (%)
24 h 28/35 (80.0
24 h and 48 h 7/35 (20.0
isk factors, no. (%)
Previous MI 4/35 (11.4
Previous PCI/CABG 8/35 (22.9
Hypertension 18/35 (51.4
Diabetes 10/35 (28.6
Hypercholesterolemia 17/35 (48.6
tatins within 10 days before randomization
CYP3A4-metabolized 20 (57.1
Non–CYP3A4-metabolized 2 (5.7%
No/unknown 13 (37.1
urrent smoker (5 cigarettes/day) 11/35 (31.4
dmission ECG, no. (%)
ST-segment elevation (transient) 2/35 (5.7%
ST-segment depression 8/35 (22.9
eft bundle branch block 0
ositive troponin I on admission, no. (%) 10 (28.6
ABG coronary artery bypass grafting; CYP3A4 cytochrome P450 3A4 isoenzy
ntervention.DP  adenosine diphosphate.
t
t00-mg group (absolute changes: 2280, 3250, and
3540 standardized sites with 300, 600, and 900 mg,
espectively); at 6 h, stimulated P-selectin was reduced
ignificantly in the 900-mg group only as compared with the
g Clopidogrel, 600 mg
(n  34)
Clopidogrel, 900 mg
(n  34)
62.8 (11.8) 63.5 (13.0)
26 (76.5%) 26 (76.5%)
76.3 (15.3) 75.4 (13.2)
25/33 (75.8%) 27/34 (79.4%)
8/33 (24.2%) 7/34 (20.6%)
4/33 (12.1%) 6/34 (17.6%)
8/33 (24.2%) 14/34 (41.2%)
19/33 (57.6%) 21/34 (61.8%)
5/33 (15.2%) 7/34 (20.6%)
19/33 (57.6%) 19/34 (55.9%)
13 (38.2%) 13 (38.2%)
6 (17.6%) 7 (20.5%)
15 (44.1%) 14 (41.2%)
8/33 (24.2%) 11/34 (32.4%)
3/33 (9.1%) 2/34 (5.9%)
10/33 (29.4%) 15/34 (44.1%)
0 2/34 (5.9%)
11/34 (32.4) 8/34 (23.5)
G electrocardiogram; MI myocardial infarction; PCI percutaneous coronary
igure 1. (A) Percentage inhibition of platelet aggregation after stimula-00 m
)
%)
)
%)
%)
%)
%)
%)
%)
%)
%)
)
%)
%)
)
%)
)ion with 5 mol/l adenosine diphosphate (ADP). (B) Percentage inhibi-
ion of platelet aggregation after stimulation with 20 mol/l ADP.
3

r
p
(
6
d
a
i
p
a
w
p
r
d
K
T
T
r
t
n
P
a
i
b
b
s
a
fi
v
r
M
c
L
h
i
i
t
s
S
t
c
b
t
D
T
d
e
e
d
p
d
f
p
t
i
3
b
a
d
d
A
a
w
S
c
I
(
b
i
b
d
i
m
m
g
F
t
F
(
i
c
935JACC Vol. 48, No. 5, 2006 Montalescot et al.
September 5, 2006:931–8 The ALBION Trial00-mg group (absolute changes: 5180, 5370, and
5470 standardized sites with 300, 600, and 900 mg,
espectively); at 6 h, stimulated fibrinogen binding to the
latelet membrane decreased in all three study groups
405, 490, and 489 fluorescence count in the 300-,
00-, and 900-mg groups, respectively, without significant
ifferences between groups).
The absolute platelet content of phosphorylated VASP,
s measured after the dual effect of PGE1 and ADP,
ncreased after ADP inhibition of the adenylate cyclase
athway. This increase was dose dependent at 6 h (Fig. 3A),
nd similar results were observed at 24 h. The VASP index,
hich calculates the relative ADP-dependent inhibition of the
latelet adenylate cyclase pathway, also exhibited a dose-
esponse effect that favored the 900-mg group (Fig. 3B), a
ifference that was still present at 24 h.
inetics of markers of inflammation and myonecrosis.
emporal changes in markers of inflammation are shown in
able 3. At 24 h, there was a trend toward an increasing
eduction from baseline in high-sensitivity C-reactive pro-
ein with greater clopidogrel LDs, although this effect was
either significant at 24 h nor apparent at 6 h. Levels of
AI-1, sCD40L, and vWF Ag were not significantly
ffected during the first 24 h by the administration of
ncreasing LDs of clopidogrel.
Average troponin I or creatine kinase levels did not differ
etween groups at 6 h or 24 h, but this analysis is impaired
y the important interindividual variability and a lack of
ensitivity. However, on day 2, a trend was observed toward
lower incidence of increasing troponin I levels during the
rst 24 h with increasing clopidogrel LD (50.0% vs. 42.9%
s. 34.6% for 300-, 600-, and 900-mg treatment groups,
espectively, p  NS) (Fig. 4).
ajor adverse cardiac events (MACE). No deaths oc-
urred during the study. Compared with the standard 300-mg
D, the incidence of MACE was numerically lower in the
igher LD groups (300 mg, 4 patients [1 nonfatal myocardial
nfarction, 1 nonplanned PCI, 2 hospitalizations for recurrent
igure 2. Areas under the curves for inhibition of adenosine diphosphate
ADP)-induced platelet aggregation between 0 and 24 h. Error bars
ndicate standard deviations of the mean. AUC  area under the IPA
urve.schemia]; 600 mg, 2 patients [2 nonfatal myocardial infarc-
(
dions); 900 mg, 0 patients) but these differences were not
tatistically significant.
afety. There were no episodes of severe bleeding during
he trial (Table 4). The incidence of mild bleeding was
omparable in the 3 treatment groups and mainly due to
leeding at puncture sites (e.g., oozing, hematoma, subcu-
aneous bleeding).
ISCUSSION
o our knowledge, the ALBION trial is the largest ran-
omized, direct pharmacodynamic comparison of 3 differ-
nt clopidogrel LDs. Furthermore, it is the only trial to
valuate multiple time points during the first 24 h after
osing and perform blinded evaluation of biological end
oints in a core laboratory. The results of the ALBION trial
emonstrate that clopidogrel doses 300 mg can provide
aster onset of action and greater levels of IPA in patients
resenting with NSTE-ACS. A dose-response effect across
he three LDs was found for IPA using 20 mol/l ADP and
nhibition of platelet activation. Compared with a standard
00-mg LD, a 900-mg LD provides greater platelet inhi-
ition within 1 h, an effect that persisted for at least 24 h. In
ddition, there was a trend to lower occurrence of myocar-
ial necrosis with the higher LDs.
Clopidogrel-induced platelet inhibition is dose and time
ependent. In healthy subjects, maximum inhibition of
DP-induced PA was obtained within 5 h after the
dministration of a first dose of 400-mg LD of clopidogrel,
ith no further inhibition observed with a 600-mg LD (11).
imilar results were reported in coronary patients receiving
lopidogrel pretreatment before PCI, with no difference in
PA detected between 450- and 600-mg LDs of clopidogrel
14). More intriguing was the absence of a difference in IPA
etween 300 and 600 mg in a recent study, despite greater
nhibition of ADP-induced platelet activation (as assessed
y flow cytometry) with 600 mg of clopidogrel (15). These
ata are in contrast to other convincing studies demonstrat-
ng a higher IPA after the administration of clopidogrel 600
g compared with 300 mg (12,13), and evidence of reduced
yocardial necrosis and/or periprocedural events with the
reater LD (13,16).
igure 3. (Left) Mean fluorescence intensity (MFI) after the coadminis-
ration of PGE1 and adenosine diphosphate (ADP) at 6 h after dosing.
Right) Vasodilator-stimulated phosphoprotein (VASP) index at 6 h after
osing. Error bars indicate standard deviations of the mean.
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The ALBION Trial September 5, 2006:931–8Although never evaluated versus clopidogrel 300 mg in an
dequately sized clinical trial, the 600-mg LD has been used
s standard therapy in placebo-controlled trials designed to
ssess the incremental benefit of GP IIb/IIIa inhibitors
19–21), and recent European guidelines have considered
00 mg to be an acceptable LD strategy in PCI (22).
oreover, there has been no dose-ranging study conducted
o far and it was still unknown whether 600 mg was the
ptimal strategy to reach the maximal antiplatelet effect as
arly as possible. Our results suggest a gradual benefit of 600
g and 900 mg to achieve more complete P2Y12 receptor
ntagonism than 300 mg, translating into more inhibition
f both platelet activation and aggregation. The ADP
oncentrations used to induce aggregation influence the
egree of IPA, and low ADP concentrations can sometimes
licit only the primary and reversible phase of aggregation.
t has been suggested that this concentration may artificially
lunt the drug or dose effect, reduce the number of poor
esponders, and may lack clinical relevance (23–25). On the
ther hand, greater ADP concentrations can recruit more
2Y12 receptors, recruit the platelet P2Y1 receptor, and may
e more representative of highly thrombogenic clinical
ituations. From the ADP content of platelets, it is possible
o calculate that a local ADP concentration of 20 mol/l
an be easily achieved in the context of in vivo platelet
ctivation (26). Indeed, 20 mol/l ADP was more effective
han 5 mol/l in unmasking the dose-effect relationship in
he present study. Although we acknowledge the numerous
able 3. Changes in Levels of Inflammatory Markers and Tropo
Clopidogrel, 300 mg
hsCRP mean (SD), ng/ml
6 h (n) 0.6  1.8 (30)
24 h (n) 0.1  5.0 (29)
PAI-1 mean (SD), ng/ml
6 h (n) 9.2  14.7 (29)
24 h (n) 5.8  17.3 (29)
sCD40L mean (SD), pg/ml
6 h (n) 1.6  2.7 (29)
24 h (n) 1.0  1.8 (29)
vWF Ag mean (SD), %
6 h (n) 2.2  36.3 (29)
24 h (n) 5.9  37.3 (29)
sCRP  high-sensitivity C-reactive protein; PAI-1  plasminogen activator inhibt
igure 4. Proportion of patients with increased troponin over the course
f 24 h.actors contributing to the variability of PA measurements,
he multiplicity of sampling times with consistent differ-
nces at all time points suggest strongly that 900 mg
rovides the most complete P2Y12 receptor occupancy. That
ose impacts not only on the rapidity of action but also on
he level of maximum IPA. Although it was reasonable to
redict a more rapid onset of action with increasing doses,
higher maximal IPA during the first 24 h of observation
ith increasing doses, persisting beyond the 6-h timepoint,
s quite interesting. The maximal plateau IPA was reached
etween 5 and 6 h in all three groups, and the curves
emained parallel during the course of the 24-h sampling
eriod, with a persistent advantage for the 900-mg group at
4 h. The impact of higher doses also clearly reduced the
umber of patients with a lower response in a dose-related
anner. In these patients, 900 mg was associated with a 4-fold
ecrease in low IPA response compared with 300 mg, what-
ver the concentration of ADP. Our data underscore the
mportance of both the dose and sampling time when evalu-
ting the degree of platelet response to clopidogrel.
These aggregation findings are reinforced by data on
latelet activation. Measurements of activated GP IIb/IIIa
eceptor, fibrinogen binding, and P-selectin expression in-
icated less activation with the 2 higher doses of clopi-
ogrel. The VASP phosphorylation assay, which is the most
ational evaluation of ADP-induced platelet P2Y12 receptor
ctivation and, as a consequence, a specific marker of the
lopidogrel effect, demonstrated a dose-effect relationship
cross the 3 doses of clopidogrel. The mean of the absolute
uorescence intensity measured on activated platelets (PGE1
ADP), which increases with the degree of platelet inhibition
ia the P2Y12 receptors, was substantially increased in a
ose-related fashion with increasing doses of clopidogrel.
alculation of the VASP index, a measure of P2Y12-
ependent platelet reactivity, confirmed the greater inhibi-
ion obtained with increasing doses of clopidogrel.
An additional supportive line of evidence was the obser-
ation that troponin I release was blunted in a dose-related
anner with increasing doses of clopidogrel. This trend,
hich was measured during the 24-h period of medical
From Baseline by Treatment Group
opidogrel, 600 mg Clopidogrel, 900 mg p Value
0.1  3.5 (26) 0.8  7.7 (28) NS
1.2  8.3 (28) 2.0  14.4 (29) NS
15.0  17.3 (29) 4.8  20.4 (29) NS
3.1  35.7 (30) 8.0  14.5 (29) NS
1.5  3.1 (25) 2.9  3.7 (28) NS
0.7  2.3 (23) 1.8  2.8 (29) NS
4.8  45.2 (29) 3.3  33.5 (29) NS
13.8  42.1 (30) 15.1  25.1 (29) NS
sCD40L  soluble CD40 ligand; vWF Ag  von Willebrand factor antigen.nin I
Cl
reatment preceding catheterization, was nonsignificant but
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13,16,27).
At 30 days, the incidence of MACE was asymmetrically
plit between the three LD groups, with a trend favoring the
ighest LD of clopidogrel. There was no excess of severe or
oderate bleeding with the higher doses. A larger trial with
dequate statistical power would be required to confirm
hese findings.
Finally, and in contrast to previous reports suggesting a
otential anti-inflammatory effect of clopidogrel, we did not
bserve significant reductions in markers of inflammation.
t 24 h, there was a nonsignificant trend toward increasing
eduction from baseline in high-sensitivity C-reactive pro-
ein with greater clopidogrel LDs, but no evidence from the
ther inflammatory markers tested. This result is likely to be
elated to the short period of observation as well as to the
bsence of PCI (28,29).
The recent ISAR-CHOICE (Intracoronary Stenting and
ntithrombotic Regimen: Choose Between 3 High Oral
oses for Immediate Clopidogrel Effect) study also com-
ared the antiplatelet effects of the same 3 LDs (30). In this
rial, which enrolled 60 stable patients, platelet aggregom-
try measurements were restricted to baseline and 4 h after
dministration of the LD. Incremental benefit was observed
cross the 3 doses, with statistical significance limited to the
omparison between 600 and 300 mg with similar findings
or the levels of the active clopidogrel metabolite. However,
ith only a single post-treatment measurement of PA, the
SAR-CHOICE investigators had little possibility of de-
ecting differences in the onset of action according to the
D. In contrast, the present study used eight consecutive
lood samples during the first 6 h, which demonstrated a
ose-effect relationship for the onset of IPA as well as for
latelet activation as measured by VASP, a direct measure
f the action of the active clopidogrel metabolite. These 2
tudies should stimulate further investigations to determine
he optimal LD of clopidogrel.
tudy limitations. Although our study is the largest phar-
acodynamic evaluation of 3 different LDs of clopidogrel,
t remains small in size and, therefore, low power may be the
xplanation for lack of significance for some of the compar-
sons; moreover, our sample size does not allow interpreta-
ion of clinical events, which have been provided here only
or information. The unblinded nature of the study is
Table 4. Incidence of Bleeding Complications b
P
Clopidogrel, 300 mg
(n  35)
Clo
Severe bleeding 0
Moderate bleeding 1 (2.9)
Mild bleeding 10 (28.6)
Total 11 (31.4)
*Bleeding complications were categorized according to the G
bleeding category. †Fisher exact test. ‡Pearson chi-square.nother limitation, although the primary end point (IPA)nd all biological endpoints were blindly and centrally
valuated.
onclusions. The present study has shown that in moderate-
isk patients with non–ST-segment elevation acute coronary
yndromes, LDs of clopidogrel300 mg provide a more rapid
nset of action, a greater IPA plateau, less-frequent low
esponse, and greater reductions in platelet activation during
he first 24 h, which all are suggestive of a dose-effect
elationship. Favorable trends also were seen on troponin
elease and ischemic events with higher doses, with no
pparent adverse effects on safety. Our study suggests that
00 mg might induce a greater antiplatelet effect than 600
g, when compared with the standard 300-mg regimen.
hese findings require further clinical evaluation in a larger,
andomized, clinical-end point trial, ideally using a double-
lind design.
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